Hematuria News and Research

RSS
In medicine, hematuria, or haematuria, is the presence of red blood cells (erythrocytes) in the urine. It may be idiopathic and/or benign, or it can be a sign that there is a kidney stone or a tumor in the urinary tract (kidneys, ureters, urinary bladder, prostate, and urethra), ranging from trivial to lethal.
New article explores cost-effectiveness of initial diagnostic protocols for microscopic hematuria

New article explores cost-effectiveness of initial diagnostic protocols for microscopic hematuria

Pacific Edge announces commercial launch of Cxbladder Monitor in the U.S.

Pacific Edge announces commercial launch of Cxbladder Monitor in the U.S.

World Kidney Day 2016 focuses on children

World Kidney Day 2016 focuses on children

RUVICA (ibrutinib) capsules approved for treatment-naïve CLL patients

RUVICA (ibrutinib) capsules approved for treatment-naïve CLL patients

Turing Pharmaceuticals acquires rights to market Daraprim (pyrimethamine) in the U.S.

Turing Pharmaceuticals acquires rights to market Daraprim (pyrimethamine) in the U.S.

IMBRUVICA (ibrutinib) approved in Europe for treatment of Waldenstrom's macroglobulinemia

IMBRUVICA (ibrutinib) approved in Europe for treatment of Waldenstrom's macroglobulinemia

Pharmacyclics's Phase III RESONATE™ trial shows adherence to 420mg dose of IMBRUVICA improves outcomes in CLL patients

Pharmacyclics's Phase III RESONATE™ trial shows adherence to 420mg dose of IMBRUVICA improves outcomes in CLL patients

Pharmacyclics’ Ibrutinib Phase Ib/II data show ibrutinib may be safe and effective in patients with cGVHD

Pharmacyclics’ Ibrutinib Phase Ib/II data show ibrutinib may be safe and effective in patients with cGVHD

Phase III HELIOS trial results show ibrutinib combination therapy improves outcomes  in CLL/SLL patients

Phase III HELIOS trial results show ibrutinib combination therapy improves outcomes in CLL/SLL patients

Ibrutinib (IMBRUVICA) may be effective for pancreatic ductal adenocarcinoma

Ibrutinib (IMBRUVICA) may be effective for pancreatic ductal adenocarcinoma

Pharmacyclics announces positive results from IMBRUVICA Phase II study in WM patients

Pharmacyclics announces positive results from IMBRUVICA Phase II study in WM patients

New pre-clinical, clinical data for IMBRUVICA to be highlighted at AACR Annual Meeting

New pre-clinical, clinical data for IMBRUVICA to be highlighted at AACR Annual Meeting

IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Pembrolizumab shows promising results in patients with classical Hodgkin Lymphoma

Pembrolizumab shows promising results in patients with classical Hodgkin Lymphoma

IMBRUVICA demonstrates anti-tumor activity against multiple myeloma in Phase II study

IMBRUVICA demonstrates anti-tumor activity against multiple myeloma in Phase II study

Alport syndrome: an interview with Dr Paul Grint, CMO, Regulus

Alport syndrome: an interview with Dr Paul Grint, CMO, Regulus

Janssen announces submission of IMBRUVICA sNDA to FDA for WM treatment

Janssen announces submission of IMBRUVICA sNDA to FDA for WM treatment

Pacific Edge signs agreement with SCPMG to evaluate Cxbladder User Program

Pacific Edge signs agreement with SCPMG to evaluate Cxbladder User Program

FDA accepts Pharmacyclics' IMBRUVICA sNDA for review

FDA accepts Pharmacyclics' IMBRUVICA sNDA for review